At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Post-Mkt 12-11 16:40:57 EST
36.05
-0.15
-0.41%
盘后36.05
+0.000.00%
16:10 EST
High36.99Low35.78Vol1.48M
Open36.04D1 Closing36.20Amplitude3.33%
Mkt Cap2.85BTradable Cap2.01BTotal Shares79.14M
T/O53.63MT/O Rate2.65%Tradable Shares55.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing
Simply Wall St.  ·  12-01
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing
BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  11-27
BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares
Reuters  ·  11-22
Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares
Mineralys Therapeutics Q3 EPS USD -0.52
Reuters  ·  11-20
Mineralys Therapeutics Q3 EPS USD -0.52
Mineralys Therapeutics Shares Fall Following Executives' Stock Sale
MT Newswires Live  ·  11-15
Mineralys Therapeutics Shares Fall Following Executives' Stock Sale
Mineralys Therapeutics falls -13.9%
TIPRANKS  ·  11-14
Mineralys Therapeutics falls -13.9%
Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares
Reuters  ·  11-14
Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares
Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  11-12
Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets
Stock Track  ·  11-11
Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets
Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  11-11
Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
LifeSci Capital Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  11-11
LifeSci Capital Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  11-11
Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. : Wells Fargo Raises Target Price to $55 From $50
THOMSON REUTERS  ·  11-11
Mineralys Therapeutics, Inc. : Wells Fargo Raises Target Price to $55 From $50
Mineralys Therapeutics files automatic mixed securities shelf
TIPRANKS  ·  11-11
Mineralys Therapeutics files automatic mixed securities shelf
Mineralys Therapeutics Inc - in Addition, Offering of up to $300 Mln of Common Stock
THOMSON REUTERS  ·  11-11
Mineralys Therapeutics Inc - in Addition, Offering of up to $300 Mln of Common Stock
Mineralys Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
THOMSON REUTERS  ·  11-11
Mineralys Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q3 Loss $0.52, vs. FactSet Est of $0.61 Loss
MT Newswires Live  ·  11-11
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q3 Loss $0.52, vs. FactSet Est of $0.61 Loss
Mineralys Therapeutics Q3 net loss narrows
Reuters  ·  11-11
Mineralys Therapeutics Q3 net loss narrows
BRIEF-Mineralys Therapeutics Q3 EPS USD -0.52
Reuters  ·  11-11
BRIEF-Mineralys Therapeutics Q3 EPS USD -0.52
Mineralys Therapeutics (MLYS): Assessing Valuation Following Positive Phase 3 Results for Lorundrostat and FDA Filing Plans
Simply Wall St.  ·  11-09
Mineralys Therapeutics (MLYS): Assessing Valuation Following Positive Phase 3 Results for Lorundrostat and FDA Filing Plans

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--